Please login to the form below

Not currently logged in
Email:
Password:

BMS melanoma drug meets goal

Bristol-Myers Squibb has announced that its investigational melanoma drug ipilimumab has performed well in a phase III study

Bristol-Myers Squibb (BMS) has announced that its investigational melanoma drug ipilimumab has performed well in a phase III study.

The trial, known as study 024, showed that ipilimumab improved overall survival in previously untreated patients with unresectable stage III or stage IV melanoma. The trial compared the BMS drug in combination with dacarbazine chemotherapy to the chemotherapy regimen alone.

BMS said it plans to submit an abstract of the data to the American Society of Clinical Oncology for presentation at the society's Annual Meeting this summer.

BMS has already filed the drug with the US Food and Drug Administration (FDA), as well as regulatory authorities in a number of other countries, as a therapy for previously treated unresectable stage III or stage IV melanoma patients. In the US, a decision regarding the drug for that indication is due within days.

22nd March 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics